Phase II, dose ranging study of the safety and immunogenicity of single dose West Nile vaccine in healthy adults ≥50 years of age

Vaccine

Volumn 30, Issue 47, 2012, Pages 6656-6664

  Dayan, Gustavo H ^a   Bevilacqua, Joan ^b   Coleman, Dorothy ^a   Buldo, Aileen ^a   Risi, George ^c  

^a SANOFI PASTEUR   (France)

^b Sanofi Pasteur   (Canada)

^c Infectious Disease Specialists   (United States)

Author keywords

Clinical trial; Older adults; West Nile virus vaccine

Indexed keywords

CHIMERIVAX; NEUTRALIZING ANTIBODY; PLACEBO; UNCLASSIFIED DRUG; WEST NILE VACCINE;

ADULT; AGED; ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG FEVER; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG WITHDRAWAL; FATIGUE; FEMALE; HUMAN; HUMAN EXPERIMENT; IMMUNOGENICITY; INJECTION SITE ERYTHEMA; INJECTION SITE PAIN; MALAISE; MALE; MULTICENTER STUDY; MYALGIA; NORMAL HUMAN; PATIENT COMPLIANCE; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RHINOPHARYNGITIS; SEROCONVERSION; SINGLE DRUG DOSE; VIREMIA; VIRUS NEUTRALIZATION; WEST NILE FEVER;

AGED; ANIMALS; ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; CERCOPITHECUS AETHIOPS; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; MIDDLE AGED; NEUTRALIZATION TESTS; UNITED STATES; VACCINES, ATTENUATED; VERO CELLS; VIRAL PLAQUE ASSAY; VIREMIA; WEST NILE VIRUS; WEST NILE VIRUS VACCINES; YELLOW FEVER VIRUS;

EID: 84867484089     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2012.08.063     Document Type: Article

References (47)

1. Sampathkumar P. West Nile virus: epidemiology, clinical presentation, diagnosis, and prevention. Mayo Clin Proc 2003, 78(9):1137-1143.
2. Marfin A.A., Gubler D.J. West Nile encephalitis: an emerging disease in the United States. Clin Infect Dis 2001, 33(10):1713-1719.
3. Watson J.T., Pertel P.E., Jones R.C., Siston A.M., Paul W.S., Austin C.C., et al. Clinical characteristics and functional outcomes of West Nile fever. Ann Intern Med 2004, 141:360-365.
4. Centers for disease control. West Nile Virus: Prevention Information and Guidance for Clinicians. Available at: [Accessed 14.011.11]. http://www.cdc.gov/ncidod/dvbid/westnile/clinicians/pdf/wnv-prevention-clinguidance.pdf.
5. Nash D., Mostashari F., Fine A., Miller J., O'Leary D., Murray K., et al. The outbreak of West Nile virus infection in the New York City area in 1999. N Engl J Med 2001, 344(24):1807-1814.
6. CDC. West Nile virus activity - United States, 2009. MMWR 2010;59:769-72.
7. CDC. West Nile virus disease and other arboviral diseases - United States, 2010. MMWR 2010;60(30):1009-13.
8. CDC. West Nile virus statistics, surveillance, and control. Available at: [Accessed: 09.08.12]. http://www.cdc.gov/ncidod/dvbid/westnile/surv%26controlCaseCount12_detailed.htm.
9. Byron M., Koraka P., Osterhaus A. West Nile virus: is a vaccine needed?. Curr Opin Investig Drugs 2010, 11(2):139-146.
10. Monath T.P., Arroyo J., Miller C., Guirakhoo F. West Nile virus vaccine. Curr Drug Targets Infect Disord 2001, 1(May (1)):37-50.
11. Tesh R.B., Arroyo J., Travassos Da Rosa A.P., Guzman H., Xiao S.Y., Monath T.P. Efficacy of killed virus vaccine, live attenuated chimeric virus vaccine, and passive immunization for prevention of West Nile virus encephalitis in hamster model. Emerg Infect Dis 2002, 8(12):1392-1397.
12. Arroyo J., Miller C., Catalan J., Myers G.A., Ratterree M.S., Trent D.W., et al. ChimeriVax-West Nile virus live-attenuated vaccine: preclinical evaluation of safety, immunogenicity, and efficacy. J Virol 2004, 78(22):12497-12507.
13. Monath T.P., Liu J., Kanesa-Thasan N., Myers G.A., Nichols R., Deary A., et al. A live, attenuated recombinant West Nile virus vaccine. Proc Natl Acad Sci USA 2006, 103(17):6694-6699.
14. Biedenbender R., Bevilacqua J., Gregg A.M., Watson M., Dayan G.H. Phase II randomized, double-blind, placebo-controlled, multi-center study to investigate the immunogenicity and safety of a West Nile Vaccine in healthy adults. J Infect Dis 2011, 203(1):75-84.
15. Jovanovic B.D., Levy P.S. A look at the rule of three. Am Stat 1997, 51(2):137-139.
16. Ng T., Hathaway D., Jennings N., Champ D., Chiang Y.W., Chu H.J. Equine vaccine for West Nile virus. Dev Biol 2003, 114:221-227.
17. Minke J.M., Siger L., Karaca K., Austen L., Gordy P., Bowen R., et al. Recombinant canarypoxvirus vaccine carrying the prM/E genes of West Nile virus protects horses against a West Nile virus-mosquito challenge. Arch Virol 2004, 18(Suppl.):221-230.
18. Davis B.S., Chang G.J., Cropp B., Roehrig J.T., Martin D.A., Mitchell C.J., et al. West Nile virus recombinant DNA vaccine protects mouse and horse from virus challenge and expresses in vitro a noninfectious recombinant antigen that can be used in enzyme-linked immunosorbent assays. J Virol 2001, 75(9):4040-4047.
19. Posadas-Herrera G., Inoue S., Fuke I., Muraki Y., Mapua C.A., Khan A.H., et al. Development and evaluation of a formalin-inactivated West Nile virus vaccine (WN-VAX) for a human vaccine candidate. Vaccine 2010, 28:7939-7946.
20. Samina I., Havenga M., Koudstaal W., Khinich Y., Koldijk M., Malkinson M., et al. Safety and efficacy in geese of a PER.C6-based inactivated West Nile virus vaccine. Vaccine 2007, 25(49):8338-8345.
21. Lim C.K., Takasaki T., Kotaki A., Kurane I. Vero cell-derived inactivated West Nile (WN) vaccine induces protective immunity against lethal WN virus infection in mice and shows a facilitated neutralizing antibody response in mice previously immunized with Japanese encephalitis vaccine. Virology 2008, 374(1):60-70.
22. Yamshchikov G., Borisevich V., Seregin A., Chaporgina E., Mishina M., Mishin V., et al. An attenuated West Nile prototype virus is highly immunogenic and protects against the deadly NY99 strain: a candidate for live WN vaccine development. Virology 2004, 330(1):304-312.
23. Yu L., Robert Putnak J., Pletnev A.G., Markoff L. Attenuated West Nile viruses bearing 3'SL and envelope gene substitution mutations. Vaccine 2008, 26(47):5981-5988.
24. Lieberman M.M., Clements D.E., Ogata S., Wang G., Corpuz G., Wong T., et al. Preparation and immunogenic properties of a recombinant West Nile subunit vaccine. Vaccine 2007, 25(3):414-423.
25. Bonafe N., Rininger J.A., Chubet R.G., Foellmer H.G., Fader S., Anderson J.F., et al. A recombinant West Nile virus envelope protein vaccine candidate produced in Spodoptera frugiperda expresSF+cells. Vaccine 2009, 27(2):213-222.
26. Sirin M.T., Travassos da Rosa A.P., Newman P., Weeks-Levy C., Coller B.A., Xiao S.Y., et al. Evaluation of the efficacy of a recombinant subunit West Nile vaccine in Syrian golden hamsters. Am J Trop Med Hyg 2008, 79(6):955-962.
27. Iglesias M.C., Frenkiel M.P., Mollier K., Souque P., Despres P., Charneau P. A single immunization with a minute dose of a lentiviral vector-based vaccine is highly effective at eliciting protective humoral immunity against West Nile virus. J Gene Med 2006, 8(3):265-274.
28. Coutant F., Frenkiel M.P., Despres P., Charneau P. Protective antiviral immunity conferred by a nonintegrative lentiviral vector-based vaccine. PLoS ONE 2008, 3(12):e3973.
29. Martina B.E., van den Doel P., Koraka P., van Amerongen G., Spohn G., Haagmans B.L., et al. A recombinant influenza A virus expressing domain III of West Nile virus induces protective immune responses against influenza and West Nile virus. PLoS ONE 2011, 6(4):e18995.
30. Martin J.E., Pierson T.C., Hubka S., Rucker S., Gordon I.J., Enama M.E., et al. A West Nile virus DNA vaccine induces neutralizing antibody in healthy adults during a phase 1 clinical trial. J Infect Dis 2007, 196(12):1732-1740.
31. Ledgerwood J.E., Pierson T.C., Hubka S.A., Desai N., Rucker S., Gordon I.J., et al. A West Nile virus DNA vaccine utilizing a modified promoter induces neutralizing antibody in younger and older healthy adults in a phase I clinical trial. J Infect Dis 2011, 203(10):1396-1404.
32. Williams J.A., Carnes A.E., Hodgson C.P. Plasmid DNA vaccine vector design: impact on efficacy, safety and upstream production. Biotechnol Adv 2009, 27(4):353-370.
33. Pletnev A.G., Claire M.S., Elkins R., Speicher J., Murphy B.R., Chanock R.M. Molecularly engineered live-attenuated chimeric West Nile/dengue virus vaccines protect rhesus monkeys from West Nile virus. Virology 2003, 314(1):190-195.
34. Kumar R., Burns E. Age-related decline in immunity: implications for vaccine responsiveness. Expert Rev Vaccines 2008, 7:467-479.
35. Pugachev K.V., Guirakhoo F., Mitchell F., Ocran S.W., Parsons M., Johnson B.W., et al. Construction of yellow fever/St Louis encephalitis chimeric virus and the use of chimeras as a diagnostic tool. Am J Trop Med Hyg 2004, 71:639-645.
36. Johnson B.W., Kosoy O., Hunsperger E., Beltran M., Delorey M., Guirakhoo F., et al. Evaluation of chimeric Japanese encephalitis and dengue viruses for use in diagnostic plaque reduction neutralization tests. Clin Vaccine Immunol 2009, 16:1052-1059.
37. Monath T.P., Cetron M., Teuwen D. Yellow fever. Vaccines 2008, 959-1055. Saunders Elsevier, Philadelphia. 5th ed. S. Plotkin, W. Orenstein, P. Offit (Eds.).
38. Hombach J., Solomon T., Kurane I., Jacobson J., Wood D. Report on a WHO consultation on immunological endpoints for evaluation of new Japanese encephalitis vaccines, WHO, Geneva, 2-3 September, 2004. Vaccine 2005, 23(45):5205-5211.
39. Smith H.L., Monath T.P., Pazoles P., Rothman A.L., Casey D.M., Terajima M., et al. Development of antigen-specific memory CD8+ T cells following live-attenuated chimeric West Nile virus vaccination. J Infect Dis 2011, 203:513-522.
40. Miller J.D., van der Most R.G., Akondy R.S., Glidewell J.T., Albott S., Masopust D., et al. Human effector memory CD8+ T cell responses to small pox and yellow fever vaccines. Immunity 2008, 28:710-722.
41. Monath T.P., Guirakhoo F., Nichols R., Yoksan S., Schrader R., Murphy C., et al. Chimeric live, attenuated vaccine against Japanese encephalitis (ChimeriVax-JE): phase 2 clinical trials for safety and immunogenicity, effect of vaccine dose and schedule, and memory response to challenge with inactivated Japanese encephalitis antigen. J Infect Dis 2003, 188(8):1213-1230.
42. Morrison D., Legg T.J., Billings C.W., Forrat R., Yoksan S., Lang J. A novel tetravalent dengue vaccine is well tolerated and immunogenic against all 4 serotypes in flavivirus-naive adults. J Infect Dis 2010, 201(3):370-377.
43. Capeding R.Z., Luna I.A., Bomasang E., Lupisan S., Lang J., Forrat R., et al. Live-attenuated, tetravalent dengue vaccine in children, adolescents and adults in a dengue endemic country: randomized controlled phase I trial in the Philippines. Vaccine 2011, 29(22):3863-3872.
44. Poo J.L., Galán Herrera J.F., Forrat R., Zambrano B., Lang J., Dayan G. Live-attenuated tetravalent dengue vaccine in dengue-naïve children, adolescents and adults in Mexico city: randomized controlled phase 1 trial of safety and immunogenicity. Pediatr Infect Dis J 2010, e9-e17.
45. Qiao M., Shaw D., Forrat R., Wartel-Tram A., Lang J. Priming effect of dengue and yellow fever vaccination on the immunogenicity, infectivity, and safety of a tetravalent dengue vaccine in humans. Am J Trop Med Hyg 2011, 85(4):724-731.
46. Hacker U.T., Jelinek T., Erhardt S., Eigler A., Hartmann G., Nothdurft H.D., et al. In vivo synthesis of tumor necrosis factor-alpha in healthy humans after live yellow fever vaccination. J Infect Dis 1998, 177(3):774-778.
47. Hacker U.T., Erhardt S., Tschöp K., Jelinek T., Endres S. Influence of the IL-1Ra gene polymorphism on in vivo synthesis of IL-1Ra and IL-1beta after live yellow fever vaccination. Clin Exp Immunol 2001, 125(3):465-469.